Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Alks save search
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
Published: 2021-10-25 (Crawled : 11:00) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 2.22%
H: 2.22%
C: 2.15%
treatment fda fda fast track fast track cancer nemvaleukin ovarian cancer fast track designation designation
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Published: 2021-08-02 (Crawled : 12:00) - biospace.com/
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 2.62%
H: 3.09%
C: 2.82%
treatment fda fda fast track fast track nemvaleukin mucosal melanoma fast track designation designation
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2021-06-01 (Crawled : 11:00) - investor.alkermes.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.29%
H: 0.28%
C: -0.95%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.79%
H: 1.4%
C: 1.31%
treatment fda schizophrenia fda approval approval
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Published: 2021-03-11 (Crawled : 12:07) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 1.56%
H: 1.79%
C: -0.1%
treatment fda drug designation
FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
Published: 2020-12-29 (Crawled : 12:07) - prnewswire.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 3.39%
H: 0.14%
C: -5.51%
drug fda submission fda acceptance new drug application resubmission
Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831
Published: 2020-10-07 (Crawled : 10:21) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.63%
H: 6.28%
C: 5.35%
fda
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2020-10-09 (Crawled : 10:21) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
| Email alert
Add to watchlist
fda schizophrenia treatment
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
Published: 2020-11-17 (Crawled : 10:21) - investor.alkermes.com
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.84%
H: 2.22%
C: 1.7%
fda response
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
BSBR | $5.25 2.54% 0.38% 430K
|
Finance
DV | News | $29.43 -2.36% 0.24% 1.9M
|
Information
JOE 4 | $54.88 1.22% 0.22% 210K
|
Finance
MUSA 4 | $417.23 1.06% 0.01% 170K
|
Retail Trade
JBI 4 | $15.14 1.34% 0.0% 2.9M
|
SBS | $15.49 -1.59% -0.84% 4.6M
|
Utilities
ML 4 | $69.13 -4.48% -1.64% 110K
|
Your saved searches
Save your searches and get alerts when important news are released.